Cresset Asset Management’s ARS Pharmaceuticals SPRY Stock Holding History
Bought
Maintained
Sold
Other funds holding SPRY
Cresset Asset Management's SPRY Position: Q3 2026 in Review
Cresset Asset Management increased its ARS Pharmaceuticals (SPRY) stake by 79% in Q3 2026, buying an estimated $139K and bringing the position to 53,952 shares worth $233K. The position accounts for ﹤0.01% of the portfolio, ranked #1624.
Cresset Asset Management first reported a position in SPRY in Q2 2024 and has held it in 10 quarters since. The position peaked at $526K in Q2 2025. 191 funds tracked by Wall St. Rank hold SPRY as of Q3 2026.
- Cresset Asset Management held 53,952 shares of ARS Pharmaceuticals worth $233K as of Q3 2026.
- Cresset Asset Management bought 23,800 ARS Pharmaceuticals shares in Q3 2026, an estimated $139K.
- ARS Pharmaceuticals made up ﹤0.01% of Cresset Asset Management's portfolio in Q3 2026, its #1624 holding.
- Cresset Asset Management first reported a position in ARS Pharmaceuticals in Q2 2024 and has held it in 10 quarters since.
- Cresset Asset Management's ARS Pharmaceuticals position peaked at $526K in Q2 2025.
- 191 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q3 2026.
Based on Cresset Asset Management's 13F filing for Q3 2026, filed 16 Nov 2026.